Overview

Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria

Status:
Completed
Trial end date:
2021-03-08
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy of stiripentol (Diacomit) as monotherapy for the treatment of primary hyperoxaluria. Pilot clinical study, open, prospective and multicenter.
Phase:
Phase 2
Details
Lead Sponsor:
Biocodex
Treatments:
Stiripentol